Welcome to our dedicated page for EVELO BIOSCIENCES news (Ticker: EVLO), a resource for investors and traders seeking the latest updates and insights on EVELO BIOSCIENCES stock.
Evelo Biosciences, Inc. (Nasdaq: EVLO) is a clinical-stage biotechnology company committed to transforming the lives of patients worldwide by developing innovative medicines known as monoclonal microbials. These therapies are orally administered and designed to modulate systemic immunology and biology by interacting directly with human cells in the gut.
Evelo’s groundbreaking approach leverages the small intestinal axis (SINTAX) to develop medicines that hold promise for a wide range of diseases, including autoimmune, immunoinflammatory, metabolic, neurological, and neuroinflammatory conditions, as well as cancer. The company's monoclonal microbials are poised to revolutionize traditional drug discovery and development by enhancing speed, reducing costs, and increasing the success rate of therapeutic outcomes.
Recent achievements at Evelo include the ongoing development of EDP2939, a next-generation product candidate for moderate psoriasis, which builds on the positive Phase 2 clinical data of its predecessor, EDP1815. Despite challenges in recent trials, Evelo remains dedicated to advancing its SINTAX platform and pursuing strategic alternatives for further development and potential partnerships.
Financially, Evelo has recently secured additional financing and restructured its debt, providing the resources needed to continue its clinical programs into 2024. The company aims to deliver therapies that are not only effective and safe but also affordable, addressing the unmet needs of millions of patients with inflammatory diseases.
Founded within VentureLabs® by Flagship Pioneering, Evelo Biosciences is a testament to innovative biotechnology with a mission to discover and develop transformative medicines for a wide array of conditions.
For more information, please visit www.evelobio.com or contact their investor and media relations teams at ir@evelobio.com and media@evelobio.com.
Evelo Biosciences (EVLO) prioritizes EDP1908 as its lead oncology candidate, demonstrating superior preclinical activity compared to EDP1503. The company will halt patient recruitment for the Phase 1/2 trial of EDP1503, which reported a 17% overall response rate (ORR) and 25% disease control rate (DCR) among patients with triple-negative breast cancer. EDP1908 has shown promise in preclinical studies, activating systemic immunity without systemic distribution, with plans to advance it into clinical trials in 2022.
Evelo Biosciences (Nasdaq: EVLO) announced positive topline results from its Phase 1b trial of EDP1815 for mild to moderate atopic dermatitis. The trial demonstrated significant improvements in Eczema Area and Severity Index (EASI) scores, with a 62% difference (p=0.034) at Day 56 compared to placebo. EDP1815 was well tolerated without serious adverse events. The drug targets Th1, Th2, and Th17-mediated inflammation, offering a novel approach to treating inflammatory diseases. Management anticipates advancing EDP1815 into later-stage trials, presenting a clear path for further development.
Evelo Biosciences (Nasdaq: EVLO) has completed patient enrollment ahead of schedule for its Phase 2 trial of EDP1815, aimed at treating mild to moderate psoriasis. The interim data readout will cover initial safety and efficacy results for the first 113 patients. EDP1815 is an oral biologic designed to address inflammatory diseases. The trial evaluates three doses of EDP1815 over 16 weeks, focusing on reduced Psoriasis Area and Severity Index (PASI) scores as the primary endpoint.
Evelo Biosciences (EVLO) has initiated the Phase 2 dose-ranging trial for EDP1815 in psoriasis, following promising data from its Phase 1b trial presented at the EADV Virtual Congress. The company anticipates six clinical readouts in psoriasis, atopic dermatitis, COVID-19, and breast cancer over the next 3-9 months. Financially, Evelo reported a net loss of $20.9 million for Q3 2020, down from $21.6 million year-over-year, with cash reserves of $81.6 million expected to sustain operations through Q3 2021.
Evelo Biosciences (Nasdaq: EVLO) has announced a conference call scheduled for October 29, 2020, at 8:30 a.m. ET to discuss its third-quarter financial results and business updates. The call can be accessed via phone or a live webcast on Evelo's investor website. The company is focused on developing orally delivered biologics that target the small intestinal axis, with promising candidates aimed at treating inflammatory diseases and cancer. Their leading products include EDP1815, EDP1867, EDP2939, and EDP1503.
Evelo Biosciences (Nasdaq: EVLO) will host a virtual key opinion leader discussion on October 22, 2020, from 9:00 a.m. to 10:30 a.m. ET, focusing on psoriasis and atopic dermatitis. Dr. Benjamin Ehst, a board-certified dermatologist, will discuss the current treatment landscape and the potential of EDP1815 as a new therapeutic option for patients with mild to moderate disease. The event will also cover the design of Evelo's recently initiated Phase 2 trial and provide an overview of clinical data for EDP1815. A live webcast will be available on Evelo's website after the event.
Evelo Biosciences has completed enrollment of 24 patients in its Phase 1b clinical trial for EDP1815, an investigational oral biologic for treating mild to moderate atopic dermatitis. The trial aims to evaluate the safety and tolerability of EDP1815, with results expected in Q1 2021. The drug has previously shown promise in psoriasis studies, indicating a potential breakthrough in treatment options for atopic dermatitis, which affects up to 10% of adults globally. The trial is crucial as current treatments are often inconvenient and unsatisfactory.
Evelo Biosciences (Nasdaq:EVLO) has initiated a Phase 2 clinical trial for EDP1815, an investigational oral biologic aimed at treating mild to moderate psoriasis. The trial aims to enroll 225 patients and will evaluate the efficacy of three doses over 16 weeks, with interim data expected by mid-2021. Previous Phase 1b studies indicated EDP1815’s potential in alleviating systemic inflammation and providing clinical benefits. The company highlights the need for better treatment options for psoriasis, emphasizing EDP1815's promising profile compared to current therapies.
Evelo Biosciences (Nasdaq: EVLO) announced the appointment of Julie Carretero as Chief People Officer. With over 20 years of experience, Carretero will lead talent acquisition and employee development. CEO Simba Gill emphasized her expertise as vital for upcoming clinical readouts, including data from EDP1815 expected by mid-2021. Evelo is advancing its pipeline of oral biologics targeting inflammatory diseases and cancer with four product candidates in development.
FAQ
What is the current stock price of EVELO BIOSCIENCES (EVLO)?
What is the market cap of EVELO BIOSCIENCES (EVLO)?
What does Evelo Biosciences specialize in?
What diseases are Evelo's medicines targeting?
What is the SINTAX platform?
What is EDP2939?
Who founded Evelo Biosciences?
Has Evelo secured financing recently?
What recent trials has Evelo conducted?
What is the mission of Evelo Biosciences?
How can I contact Evelo Biosciences for investor information?
Where can I find more information about Evelo Biosciences?
